Illumina, Inc. - Common Stock (ILMN)

What happened? Shares of genomics company Illumina (NASDAQ:ILMN) fell 17.7% in the afternoon session after the company reported third-quarter 2026 financial ...

Clinical sequencing demand drives margin expansion and full-year guidance hikes.

Illumina stock crashed Friday, despite beating third-quarter expectations, on tariff confusion and a shaky backdrop for AI.

Illumina (NASDAQ:ILMN) reported third-quarter results above its prior guidance, citing strong clinical sequencing demand, elevated NovaSeq X instrument placements and disciplined spending. The company raised its full-year revenue, operating-margin and earnings outlook, while executives said they rem

Genomics company Illumina (NASDAQ:ILMN) missed Wall Street’s revenue expectations in Q3 2026 as revenue rose 4.2% year on year to $1.13 billion. On the other...

Genomics company Illumina (NASDAQ:ILMN) will be reporting earnings this Thursday afternoon. Here’s what you need to know. Illumina beat analysts’ revenue exp...

BBH offers lower costs and concentrated large-cap exposure, while PBE delivers higher dividend income and slightly better five-year returns through a multifactor strategy.

FBT has outperformed RSPH by a wide margin recently. The question is whether you want to own the fund that won last year or the one built to hold up over many years.

RSPH offers broader healthcare exposure with lower volatility and higher dividend yield, while IBB provides concentrated biotech focus with stronger recent returns.

These two healthcare ETFs offer investors exposure to some of medicine's biggest names, but their different approaches to investing could lead to very different results.

AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio.

VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.

Check out the companies making headlines yesterday: Harley-Davidson (NYSE:HOG): American motorcycle manufacturing company Harley-Davidson (NYSE:HOG) rose by ...

What Happened? Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 9.9% in the afternoon session after EpiSign Inc. and Geneyx ...